Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain

Human Reproduction

Volumn 21, Issue 1, 2006, Pages 248-256

  Crosignani, P G ^a   Luciano, A ^b   Ray, Amrit ^c   Bergqvist, A ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

Bone mineral density; Depot medroxyprogesterone acetate; Endometriosis; Leuprolide; Pelvic pain; Subcutaneous injection

Indexed keywords

LEUPRORELIN; MEDROXYPROGESTERONE ACETATE;

ADULT; AMENORRHEA; ARTHRALGIA; ARTICLE; BONE DENSITY; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ESTROGEN DEFICIENCY; FEMALE; FOLLOW UP; HIP RADIOGRAPHY; HOT FLUSH; HUMAN; LAPAROSCOPY; LUMBAR SPINE; MASTALGIA; MULTICENTER STUDY; NAUSEA; PELVIS PAIN SYNDROME; PHASE 3 CLINICAL TRIAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; UTERUS BLEEDING;

EID: 29144488393     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dei290     Document Type: Article

References (47)

1. Ailawadi RK, Jobanputra S, Kataria M, Gurates B and Bulun SE (2004) Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study. Fertil Steril 81,290-296.
2. Bergqvist A and Theorell T (2001) Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand 80,628-637.
3. Biberoglu KO and Behrman SJ (1981) Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness. Am J Obstet Gynecol 139,645-654.
4. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putman M and Sasano H (1999) Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 6,293-301.
5. Bulun SE, Fang Z, Imir G, Gurates B, Tamura M, Yilmaz B, Langoi D, Amin S, Yang S and Deb S (2004) Aromatase and endometriosis. Semin Reprod Med 22,45-50.
6. Child TJ and Tan SL (2001) Endometriosis: Aetiology, pathogenesis and treatment. Drugs 61,1735-1750.
7. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347,1713-1727.
8. Dlugi AM, Miller JD, Knittle J and the Lupron Study Group (1990) Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Fertil Steril 54,419-427.
9. Eskenazi B and Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24,235-258.
10. Harrison RF and Barry-Kinsella C (2000) Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: A prospective, randomized, placebo-controlled study. Fertil Steril 74,24-30.
11. Hornstein MD, Hemmings R, Yuzpe AA and Heinrichs WL (1997) Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 68,860-864.
12. Jain J, Dutton C, Nicosia AF, Wajszczuk C, Bode FR and Mishell DR (2004a) Pharmacokinetics, ovulation suppression, and return to ovulation following a lower dose subcutaneous formulation of Depo-Proverar®. Contraception 70,11-18.
13. Jain J, Jakimiuk AJ, Bode FR, Ross D and Kaunitz AM (2004b) Contraceptive efficacy and safety of DMPA-SC. Contraception 70,269-275.
14. Jakimiuk A (2004) A new highly effective subcutaneous contraceptive injection [abstract]. Presented at the 8th Congress of the European Society of Contraception. Edinburgh, UK, June 23-26, 2004.
15. Jones GL, Kennedy SH and Jenkinson C (2002) Health-related quality of life measurement in women with common benign gynecologic conditions: A systematic review. Am J Obstet Gynecol 187,501-511.
16. Kaunitz AM (2000) Injectable contraception: New and existing options. Obstet Gynecol Clin North Am 27,741-780.
17. Kaunitz AM and Kipersztok S (2005) Effect of DMPA-SC 104 and DMPA-IM on bone mineral density after up to 2 years of treatment. Poster presented at: Controversies in Obstetrics, Gynecology, and Infertility. Athens, Greece, April 14-17, 2005. Poster P05.
18. Kaunitz AM and Montgomery Rice V (2005) Recovery of total hip bone mineral density following discontinuation of DMPA-IM 150 mg/mL contraceptive injection. Poster presented at the 12th World Congress of the International Academy of Human Reproduction. Venice, Italy, March 10-13, 2005. Poster 35.
19. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A and Saridogan E (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod [Epub, June 24, ahead of print].
20. Koch GG and Gansky SA (1996) Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J 30,523-534.
21. Kupperman HS, Blatt MHG, Wiesbader H and Filler W (1953) Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 13,688-703.
22. Lupron Depot [package insert] (2004) Tap Pharmaceuticals. Lake Forest, III.
23. Marques A, Bahamondes L, Aldrighi JM and Petta CA (2004) Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. J Reprod Med 49,115-120.
24. Montgomery Rice V and Kaunitz AM (2005) Evaluation of T-scores during use and following discontinuation of intramuscular depot medroxyprogesterone acetate 150 mg/mL contraceptive injection. Poster presented at: 12th World Congress of the International Academy of Human Reproduction, Venice, Italy, March 10-13.
25. Pelkman C (2002) Hormones and weight change. J Reprod Med 47,791-794.
26. Pelkman CL, Chow M, Heinbach RA and Rolls BJ (2001) Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 73,19-26.
27. Rice VM (2002) Conventional medical therapies for endometriosis. Ann NY Acad Sci 955,343-352.
28. Rotondi M, Labriola D, Rotondi M, Ammaturo FP, Amato G, Carella C, Izzo A and Panariello S (2002) Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol 23,523-526.
29. Saito T, Yoshizawa M, Yamauchi Y, Kinoshita S, Fujii T, Mieda M, Sone H, Yamamoto Y and Koizumi N (2003) Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittel-Forschung 53,507-514.
30. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE and Ott SM (2002) Injectable hormone contraception and bone density: Results from a prospective study. Epidemiology 13,581-587.
31. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE and Ott SM (2005) Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 159,139-144.
32. Schweppe K-W (2001) Current place of progestins in the treatment of endometriosis-related complaints. Gynecol Endocrinol 15 (Suppl 6),22-28.
33. Shaw RW (2003) Evaluation of the role of laser treatment for the treatment of pain in endometriosis. Ann NY Acad Sci 997,240-246.
34. Stager MM and Cromer BA (2000) Management of clinical side effects of DMPA. J Pediatr Adolesc Gynecol 13,147-149.
35. Sutton CJG, Ewen SP, Whitelaw N and Haines P (1994) Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 62,696-700.
36. Takayama K, Zeitoun K, Gunby RT, Sasano H, Carr BR and Bulun SE (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69,709-713.
37. Valle RF and Sciarra JJ (2003) Endometriosis: Treatment strategies. Ann NY Acad Sci 997,229-239.
38. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S and Crosignani PG (1996) Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 175,396-401.
39. Vercellini P, Cortesi I and Crosignani PG (1997) Progestins for symptomatic endometriosis: A critical analysis of the evidence. Fertil Steril 68,393-401.
40. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E and Crosignani PG (2003a) Progestogens for endometriosis: Forward to the past. Hum Reprod Update 9,387-396.
41. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R and Crosignani PG (2003b) Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80,560-563.
42. Viganò P, Mangioni S, Odorizzi MP, Chiodini A, Rocca S and Chiodo I (2003) Use of estrogen antagonists and aromatase inhibitors in endometriosis. Curr Opin Invest Drugs 4,1209-1212.
43. Westhoff C (2003) Depot-medroxyprogesterone acetate injection (Depo-Proverar®): A highly effective contraceptive option with proven long-term safety. Contraception 68,75-87.
44. Wheeler JM (1989) Epidemiology of endometriosis-associated infertility. J Reprod Med 34,41-46.
45. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1997) Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. Lancet 349,1202-1209.
46. Winkel CA (2000) A cost-effective approach to the management of endometriosis. Curr Opin Obstet Gynecol 12,317-320.
47. Winkel CA (2003) Evaluation and management of women with endometriosis. Obstet Gynecol 102,397-408